
VCEL • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold VCEL in your mock portfolio yet.
A PE ratio above 140 on EPS of $0.26 implies the market is already pricing in very strong future growth, leaving limited margin for error. While positive earnings are a constructive sign for a specialty biotech/medtech name, the valuation looks stretched relative to current profitability. Without evidence of accelerating earnings growth, the risk/reward appears balanced rather than clearly favorable.
The stock trades at $36.49, modestly below its 200-day moving average of $39.24, indicating a slight intermediate-term downtrend but not a severe technical breakdown. A 6.5% decline over the last month shows some recent pressure, yet an RSI of 55.57 is firmly in neutral territory, suggesting neither overbought nor oversold conditions. Overall, the technical picture points to consolidation rather than a clear bullish or bearish trend.
Website traffic at roughly 6,900 visitors per month and flat job openings suggest a stable but not rapidly expanding commercial footprint. Social media signals are mixed: small declines in Twitter/X and Facebook followers contrast with modest growth on LinkedIn, which is more aligned with professional and industry engagement. Overall, alternative data point to a steady business presence without strong evidence of accelerating demand or brand momentum.
Vericel shows positive earnings but trades at a very high valuation multiple, while its stock price sits modestly below its 200-day moving average with neutral momentum indicators. Alternative data portray a stable but not rapidly accelerating business footprint. Taken together, the evidence supports a neutral stance: the company has strengths, but the current valuation and lack of strong growth signals temper a clearly bullish view.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: